Background: Treatment of vivax malaria with primaquine prevents the relapse of infection from residual liver stages of the parasite. Inadequate dosage is related to a higher relapse risk.
Following an outbreak of primarily falciparum malaria among Australian Defence Force (ADF) personnel during the InterFET (International Force, East Timor) operation in East Timor (September 1999 -February 2000 , 267 vivax malaria cases and relapses were reported to the Central Malaria Register (CMR) of the Army Malaria Institute by September the following year. 1 To prevent vivax (and ovale) malaria, primaquine postexposure prophylaxis (PEP) may be used following travel to malarial areas. 2 In the ADF, primaquine PEP is not directly observed by routine. Nevertheless, for almost 10 years, this has been found to be effective against malaria exposures in the regions to the near north of Australia. 3 Prior to the ADF involvement in East Timor, the policy for the primaquine PEP dose for this region was raised from 15 mg daily to 22.5 mg daily for 14 days.
Initial investigations of primaquine during the 1950s were conducted using the Chesson strain from the southwest Pacific. Investigators found 30 mg/d for 14 days was effective, 4, 5 whereas 15 mg daily of primaquine was only 70 to 80% effective. Later the total dose of primaquine was suggested as the salient feature of treatment, 6 and 6 mg/kg was ultimately recommended for effective treatment. 7 In recent studies of primaquine efficacy among Australians being treated for vivax malaria, resistance was suggested by a relapse rate of infections from Papua New Guinea in returning Australians that was eight times the relapse rate of infections contracted elsewhere. 8 It was further noted that for these infections, 30 mg primaquine daily for 14 days (420 mg total) was probably inadequate treatment to prevent relapses in this group of Australians.The total dose of 315 mg (22.5 mg daily for 14 days) used by our study population for PEP would only be satisfactory to treat those individuals weighing < 52.5 kg. In a sample of 1,557 Australian soldiers completing deployments from operations in Bougainville and East Timor, the average weight was 79 kg (SD 12 kg); therefore, the existing dose would be inadequate for most.
The conventional treatment of vivax malaria in the ADF is 1,500 mg chloroquine orally over 3 days followed by 14 days of primaquine at 7.5 mg three times a day (315 mg). However, during the study period 15 mg twice daily for 14 days (420 mg) began to be used for treatment, providing the opportunity for a retrospective analysis of the effectiveness of the larger dose.
Methods
The CMR was searched for cases of vivax malaria presenting between September 1999 and September 2001, with which service in East Timor was recorded. Only those records with dates recorded for both departures from the malarial area and diagnosis as well as details of the primaquine treatment used prior to relapse were included. From this group a series of relapsing vivax malaria cases were specifically reviewed.
Three hundred eighteen reports fulfilled the inclusion criteria. Nineteen records indicated deployment to others areas north of Australia known to be malarial in addition to East Timor, namely, Papua New Guinea and Solomon Islands. The total includes 241 initial cases (primary parasitemia) of vivax malaria and 77 clinical episodes of relapsing vivax malaria, of which 5 were considered recrudescent.
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Results
The 241 initial cases of vivax malaria had a mean time to onset after departure from the malarial area of 119 days (range 4-507 d after return to Australia).The median time to onset after repatriation to Australia was 89 days.
From approximately 7,000 ADF personnel serving on East Timor with InterFET for approximately 5 months (the operation continued for several years under the name of the United Nations Transitional Administration in East Timor), 230 primary vivax malaria cases were recorded.The primary vivax attack rate is approximately 3.3% or 8 cases per 100 person-years of exposure.
Of the 318 clinical episodes included, 77 clinical episodes of vivax malaria were second or subsequent episodes of parasitemia, classified as relapses. These included 55 primary relapses or second episodes of parasitemia found on clinical presentation. Forty-four of these relapses occurred within 180 days after the initial episode of parasitemia, a relapse rate of 18% at 6 months.
Multiple relapses have also been reported (not limited to within 6 months). Seventeen of the 55 patients with primary relapses have developed a second relapse, or third episode of parasitemia. Of these, 4 patients progressed to a third relapse (fourth parasitemia), and 1 has been treated for 4 relapses, or 5 clinical episodes with Plasmodium vivax parasitemia (Table 1) . 10 With all relapses included, the mean time to relapse was 137 days. Lag times to relapse were dispersed from 21 days after the previous episode to a maximum lag time to relapse of 484 days (SD 105 d) .The median time to relapse was 94 days.
From the CMR, 146 cases of primary vivax malaria with complete, documented primaquine treatment data were identified and reviewed.Those treated with a total dose of 315 mg of primaquine were more likely to relapse (RR 6.63, CI 2.75-15.96) than were those treated with a total dose of 420 mg (Table 2) .
Discussion
Other than recrudescence within the pharmacologically active period after chloroquine treatment,the rate of vivax relapse following treatment reflects responsiveness to primaquine.A rate of 20 to 30% failure is consistent with that reported from the early studies of primaquine against Chesson strain P. vivax. 5 Also, the rate is close to that found more recently in Australia upon treating civilians for the infection following travel to Papua New Guinea and other parts of the southwest Pacific. 8 However, the lack of observed compliance suggests these are underestimates of the true efficacy of primaquine.
It is possible that parasites presenting in relapse infections and multiple relapses are more recalcitrant to primaquine than in primary infections.This would suggest that relapse infections are more likely to relapse further; however, contrary to this is that with increasing age of the hypnozoites, relapses cease.These influences may be irrelevant or counteracting as lag times from the last primaquine dosage to the first clinical episode are notably similar to those between clinical episodes.
Conclusion
The available data presented here suggest that vivax malaria in this region is increasingly tolerant of the 22.5 mg daily treatment regimen of primaquine and that the greater dose of at least 30 mg daily is more effective.
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